Cow Milk Protein Allergy Market Size and Growth Outlook 2024-2035

Introduction

NextGen Intelligence Stats reveals that, with a current value of approximately US$ 799.44 million in 2024, the global Cow Milk Protein Allergy (CMPA) Market is expected to grow considerably. 

By 2035, the CMPA market is expected to reach CBS 2,000 at nearly US$ 1,863.36 million, with a strong compound annual growth rate (CAGR) of 7.6% between 2025 to 2035.

The market will continue to grow due to the increasing demand for specialty nutritional and therapeutic alternatives for the management of CMPA across the globe.

CMPA is an immunological reaction (as opposed to lactose intolerance, which is fermentation of nearly all known food proteins), that occurs primerily due to the introduction of specific proteins found in cow's milk. CMPA primarily affects infants with the most common occurrence being in children aged under one year of age.

CMPA is experiencing enormous change in the scope of CMPA management, in terms of product improvements, clinical research, innovation and consumer demands for safer, specialty infant nutrition.

Market Dynamics

Growing Awareness and Diagnosis

Parental and pediatrician awareness of cow milk allergy CMPA, combined with easier recognition of symptoms these days have resulted in more frequent and improved screening for CMPA, which has led to more frequent diagnosis of CMPA in children and infants than ever before.

Government programs and healthcare campaigns promoting early diagnosis are being established worldwide. Diagnostic tools like the Cow's Milk-related Symptom Score (CoMiSS) help to provide a standardized approach to recognize the symptoms of CMPA.

All of these diagnosed cases leads to an increase in the demand for more specialty infant formulas and nutrition products dealing strictly with CMPA.

Increasing Incidence in Infants

The CMPA incidence worldwide varies from 0.5% to 7%, varying by location and local medical practices. As better attention is placed on infant health, many new cases of CMPA are being diagnosed that were previously unconsidered, further expanding population size.

CMPA usually presents in the infant's first year of life and occurs as both IgE-mediated and non-IgE-mediated allergy treatments requiring different treatment pathways.

Product Innovations

Companies that are currently operating in the CMPA products space, are developing extensive hydrolyzed formulas (eHFs) and amino acid-based formulas (AAFs) that focus on either avoiding allergenicity considerations, while maximizing growth and benefits for infants. The trend in AAF usage is growing among infants with CMPA - especially the more severe CMPA. Companies are currently exploring organic, plant-based and other alternative formulas as well.

Market Scope

By Type of Allergy Reaction

• IgE-Mediated CMPA

This segment will take the largest share of the market due to the immediate allergic reactions occurring quickly after consuming cow milk, which leads all allergy diagnosis to be developed in a timely manner through blood and skin prick tests. 

• Non-IgE-Mediated CMPA

This segment is likely to show the highest growth rate because diagnostic efforts on non-IgE-mediated reactions require more robust and complex consideration to evaluate a cautious diagnosis. Increasing awareness and use of up-to-date diagnostic techniques will be a related consideration for market growth in this area.

By Product Category

• Extensively Hydrolyzed Formulas (eHFs)

• Amino Acid-Based Formulas (AAFs)

• Soy-Based Formulas

• Rice-Based Formulas

• Other hypoallergenic Products

• Extensively Hydrolyzed Formulas (eHFs) 

This is the most common type of product, and the most popular for mild to moderate CMPA, eHFs offered clinically studied efficacy and the availability with a reasonable cost. 

• Amino Acid-Based Formulas (AAFs)

This product type is forecast to grow quicker than other products, because they are designed for serious allergy cases, and provide potential clinical advantages, and prolonged safety for infants with CMPA. 

By End User

• Infants (0-12 months)

• Toddlers (1-3 years)

• Children (Older than 3 years)

• Infants (0-12 months) 

This is the largest end user segment of the three considered above, and with population demand is strong, because most CMPA symptoms are discovered in this group.

• Toddlers (1-3 years)

This market segment is rapidly growing, relative to the population of cases with CMPA, as there are more instances of persisting CMPA beyond the infancy. Toddlers with CMPA have specialized nutrition in order to exhibit a longer term maintenance of their symptoms by using the product(s). 

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

• Supermarkets/Hypermarkets

• Pharmacy/Retail Stores

The sales channel - pharmacy represents the largest channel, as those pharmacies are reputable, and will dispense CMPA formula products that were medically recommended.

• Online Retail

Finally, this is the fastest-growing channel, it provides users convenience, large selection of products, pricing transparency with the users, and subscription options.

Regional Analysis  

Asia Pacific  

The Asia Pacific region dominates global market share in CMPA products, owing to high birth rates, increasing CMPA diagnoses, and high health expenditure.

Countries such as China and India are also important markets, along with emerging government programs focused on improving infant health. Further, CMPA products increasingly available through hospitals and pharmacies, improves growth. 

North America  

North America is expected to grow the fastest supported by superior health infrastructure, high awareness, and an existing strong base of major CMPA products. The widespread use of diagnostic tools and access to specialty formula increases demand.  

Europe  

Europe is the third largest regional market with established health systems and a robust regulatory framework based on product safety, helps drive steady growth. There is a strong demand for extensively hydrolyzed and amino-acid-based formula.  

Rest of the World (South America, Middle East & Africa)  

This region is growing slower due to access to healthcare and lower awareness, however, urbanization, expanding retail channels and increasing health education is slowly emerging new markets.  

Competitive Landscape

The leading market players are focused on:

• Research and product development: Companies are investing in clinically validated, hypoallergenic, and more nutritious formulation. This research and product development will improve the effectiveness of the formulations and reduce allergic responses.

• Strategically partnering and expanding reach: companies are partnering with healthcare providers, entering attractive emerging markets, and improving products access.

• Marketing and informing: continues to raise awareness of CMPA while also assisting in diagnosis as soon as possible for parents and healthcare providers.

Dive Into Our In-Depth Market Analysis:  https://nextgenintelligencestats.com/cow-milk-protein-allergy-market

Market Outlook and Trends

• Global awareness is growing: As educational campaigns by governments and NGOs continue, CMPA is being diagnosed sooner and access to treatment will improve.

• Improved diagnosis: with tools like CoMiSS and better testing for immunologic physiology, CMPA cases can be determined more quickly and accurately.

• Changing formulas: By expanding options for organic, plant-based, and unique amino acid profiles, there is greater consumer choice on the market that encompasses innovative options.

• Distribution expansion: E-commerce and retail access are going to increase the distribution reach for the market.

• Local growth: developed markets are grown but emerging markets offer greater opportunity for growth when combined with increased awareness and improvements in access to healthcare.

These are the main players within the Cow's Milk Protein Allergy (CMPA) market based on industry knowledge and NextGen Intelligence Stats data. The Key Players in the Cow Milk Protein Allergy Market

• Nestlé Health Science – A global player that has both extensively hydrolyzed formulas and amino-acid based formulas that were made specifically to treat CMPA issues.

• Danone Nutricia – Offers a wide range for specialized infant nutrition and have products with hypoallergenic options for those dealing with CMPA.

• Abbott Laboratories – They offer CMPA formulas that have been clinically tested and they have a strong presence in developed and emerging markets.

• Mead Johnson Nutrition (a subsidiary of Reckitt Benckiser Group) – They offer hypoallergenic formulations geared towards infant formulas and infant allergy management.

• Hero Group - They offer organic milk protein allergy nutrition brands and specialized nutrition for children.

• Holle Baby Food GmbH - A European player whose focus is also on organic and allergen formula with cow's milk protein for infants with CMPA.

• Bayers (Bayer AG) - They produce medical and healthcare products and market nutrition supplements relevant to CMPA.

• Fonterra Co-operative Group - A major dairy company with a number of brands offering dedicated product lines for hypoallergenic products improving the quality of care for infants.

• FrieslandCampina – They provide specialized infant formulas targeting the infant's allergy-related nutritional needs.

• ByHeart - New and innovative company providing clinically supported hypoallergenic nutrition.

The companies that we assessed are leading innovation, distribution, and research in the CMPA market, that drive product development and global access to safer infant nutritional products.

Their competitive strategies incorporate R&D spending, strategic partnerships, and targeted marketing to increase diagnosis and treatment of CMPA according to NextGen Intelligence Stats proprietary information.

Conclusion

The Cow Milk Protein Allergy Market is set to grow steadily, robustly due to increased diagnosis, improved awareness, and enhanced nutritional solutions.

With projected growth in market value due to changing infant health-care trends and expanding product categories, companies and health-care stakeholders should focus on innovative, safe, and accessible CMPA options.

Discover Market Trends – Request a Complimentary Sample: https://nextgenintelligencestats.com/request-sample-report/69